InsiderSignal.AI

InsiderSignal.ai

ROIV - Roivant Sciences Ltd.

Insider Sale by Gline Matthew (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Gline Matthew, serving as CEO at Roivant Sciences Ltd. (ROIV), sold 289,774 shares at $29.16 per share, for a total transaction value of $8,449,810.00. Following this transaction, Gline Matthew now holds 16,736,116 shares of ROIV.

This sale represents a 2.00% decrease in Gline Matthew's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, April 16, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 20, 2026, 4 days after the trade was made.

Roivant Sciences Ltd. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Gline Matthew

Gline Matthew

CEO

Matthew Gline is the Chief Executive Officer of Roivant Sciences Ltd. (ROIV), a multinational healthcare company pioneering a 'hub-and-spoke' model by building and managing subsidiary life sciences ventures focused on drug development.[[1]](https://milkeninstitute.org/events/global-conference-2022/speakers/matthew-gline)[[2]](https://roivantsv.org/team-bios/matt-gline)[[4]](https://www.investmentreports.co/interview/matt-gline-1524) He joined Roivant in March 2016, serving as Chief Financial Officer from 2017 to 2021 before ascending to CEO, and also holds roles as Secretary and Board Member.[[1]](https://milkeninstitute.org/events/global-conference-2022/speakers/matthew-gline)[[2]](https://roivantsv.org/team-bios/matt-gline) Gline's career highlights include prior roles as Vice President at Goldman Sachs in Fixed Income Digital Structuring (2014-2016), focusing on technology and data strategy, co-founder of Fourthree (a risk analytics firm), and Vice President at Barclays in Enterprise Risk Management Advisory (2008-2012).[[1]](https://milkeninstitute.org/events/global-conference-2022/speakers/matthew-gline)[[2]](https://roivantsv.org/team-bios/matt-gline) Under his leadership, Roivant achieved a landmark deal in 2023, selling its inflammatory bowel disease therapy RVT-3101 to Roche for at least $7.1 billion, earning him recognition as one of biotech's top CEOs.[[3]](https://www.statnews.com/status-list/2024/matt-gline/) He holds an A.B. in Physics from Harvard College.[[1]](https://milkeninstitute.org/events/global-conference-2022/speakers/matthew-gline)[[2]](https://roivantsv.org/team-bios/matt-gline)

View full insider profile →

Trade Price

$29.16

Quantity

289,774

Total Value

$8,449,810.00

Shares Owned

16,736,116

Trade Date

Thursday, April 16, 2026

5 days ago

SEC Filing Date

Monday, April 20, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Roivant Sciences Ltd.

Company Overview

No company information available
View news mentioning ROIV

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5808843

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime